Anixa’s Ovarian Cancer Trial Progress: Promising Results

Anixa Biosciences Advances Phase 1 Clinical Trial for Ovarian Cancer Therapy

Anixa Biosciences has entered the next phase of its Phase 1 clinical trial for a cutting-edge ovarian cancer therapy in partnership with the Moffitt Cancer Center. The trial focuses on chimeric antigen receptor T-cell (CAR-T) therapy, specifically designed for patients with recurrent ovarian cancer who have not seen success with previous treatments. The company has now escalated the dosage for the new cohort, with the fourth patient receiving a triple dose of CAR-T cells compared to the initial patients.